Item 8.01. Other Events.

On June 4, 2020, Tetraphase Pharmaceuticals, Inc. (the "Company") received notice that the United States Food and Drug Administration (the "FDA") approved the Company's supplemental New Drug application ("sNDA") for a new strength of XERAVATM (eravacycline) for injection for the treatment of complicated intra-abdominal infections in adult patients containing 100mg of eravacycline per vial as well as an extension of the "in-use" shelf life for XERAVA diluted ready for infusion IV solution from 7 days to 10 days under refrigerated conditions for the existing 50 mg/vial product and for the newly approved 100 mg/vial product.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses